Photo

wbryan@bcg-usa.com

 

Wilson W. Bryan, M.D.

CV in Adobe

Contact

 

EDUCATION:

M.D. University of Chicago, Pritzker School of Medicine (1982)
B.S. Chemistry, University of South Carolina, Magna Cum Laude (1978)

EXPERIENCE:
CURRENT POSITION
(Jan. 2007 - present)		   Senior Clinical Consultant Biologics Consulting Group Inc.
Rockville, MD
   

Sept. 2005 - Jan. 2007

  

Medical Officer & Team Leader, CDER, FDA, Division of Neurology Products (DNP)
Silver Spring, MD.
Oct 2003 - Sept. 2005 Medical Officer & Team Leader,CDER, FDA, Division of Therapeutic Biological Internal Medicine Products (DTBIMP), Medical Officer, Rockville, MD.
Sept. 2000 - Oct. 2003

Medical Officer,CBER, FDA, Division of Clinical Trial Design and Analysis (DCTDA),
Rockville, MD

  • Served as primary clinical reviewer and/or clinical team leader for Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs).
  • Responsibilities included review of clinical protocols, analysis of study results, representing FDA at meetings with pharmaceutical companies, and providing FDA perspective at academic conferences.
  • Experience with all phases of clinical development for the following products:
    • Drugs (small molecules)
    • Biologics, including therapeutic proteins, monoclonal antibodies, botulinum toxins, blood products (including intravenous immunoglobulins), cell therapies, and gene therapies
  • Experience with clinical development of treatments for neurological disorders, including (but not limited to) the following indications:
    • Multiple sclerosis
    • Cerebrovascular disease
    • Parkinson's disease
    • Alzheimer's disease
    • Movement disorders (e.g., cervical dystonia, tremor)
    • Amyotrophic lateral sclerosis
    • Other neuromuscular disorders (e.g., muscular dystrophy, myasthenia gravis, inflammatory myopathies, peripheral neuropathies)
    • Headache (e.g., tension headache, migraine headache)
    • Bioterrorism
    • Sleep disorders (e.g., insomnia, sleep apnea, circadian rhythm disorders)
 
1998 - 2000  

Associate Professor, Dept. of Neurology. The University of Texas Southwestern Medical Center at Dallas, Dept. of Neurology Dallas, TX

1990 - 1998 Assistant Professor, Dept. of Neurology The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
1987 - 1990

Instructor, Dept. of Neurology The University of Texas Southwestern Medical Center at Dallas, Dallas, TX

  • Medical care of patients with neurologic disorders
  • Provided inpatient and outpatient neurology consultations
  • Instruction and supervision of medical students, neurology residents, and residents from other medical services (e.g., internal medicine, psychiatry, ophthalmology), neuromuscular fellows, and clinical neurophysiology fellows
  • Clinical research with emphasis on clinical trials in neuromuscular disorders
 
1987 - 1993

Chief, Neuromuscular Disease Section, Veterans Affairs Medical Center, Neurology Service, Dallas, TX

  • Medical care of patients with neurologic disorders
  • Provided inpatient and outpatient neurology consultations
  • Instruction and supervision of medical students, neurology residents, and residents from other medical services (e.g., internal medicine, psychiatry, ophthalmology
  • Clinical research with emphasis on clinical trials in neuromuscular disorders and cerebrovascular disease
1986 - 1987

Neuromuscular Fellowship, Tufts-New England Medical Center, Boston, MA.
1985-1986

Chief Resident, The University of Texas Southwestern Medical Center at Dallas,
Dallas, TX.
1983 - 1986

Neurology Residency, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX.
1982 - 1983 Medical Internship, Grady Memorial Hospital, Emory University Hospital, Altanta, GA
LICENSURE
  • Texas Medical License No. G7917 (8/23/85-present)
  • Massachusetts Medical License No. 55940 (6/4/86 - 1/24/89)
  • Maryland Medical License No. D0058072 (10/16/01- present)
  • Virginia Medical License No. 0101232040 ( 1/29/02- present)
  • District of Columbia Medical License No. MD33451 (2/27/02 - present)
HONORS AND AWARDS
  • Trephined Cranium Award for Neurology Resident Teaching. The University of Texas Southwestern Medical Center at Dallas (1990, 1992, 1993, 1999)
CERTIFICATIONS
  • American Board of Psychiatry and Neurology
  • Neurology (#29776) 11/1987
  • Added Qualifications in Clinical Neurophysiology (#0271) 4/1994, re-certification in 2002
  • American Board of Electrodiagnostic Medicine (1990)
PROFESSIONAL MEMBERSHIPS
  • American Academy of Neurology (1984-present)
  • American Association of Electrodiagnostic Medicine (1990-2001)
  • American Society for Experimental NeuroTherapeutics (2001-present)
  • Society for Clinical Trials (2001-present)
ADMINISTRATIVE EXPERIENCE
The University of Texas Southwestern Medical Center at Dallas:
  • Co-Director, Muscular Dystrophy Association Clinic (1990-2000)
  • Co-Director, Myasthenia Gravis Association Clinic (1990-2000)
  • Co-Director, Neurology Residency Program (1990-1992)
  • Director, Neurology Residency Program (1992-1995)
  • Director, Transitional Year Residency Program (1993-1997)
  • Vice Chairman, Department of Neurology (1998-2000)

Advisory Boards:
  • ALS Clinical Assessment, Research, and Education (ALS C.A.R.E.,a national registry of ALS patients) (1995-1999)
Education Program:
   
  • Co-Director, Effective Planning and Management of Clinical Trials: Improving the Process from Protocol to Recruitment, Pharmaceutical Education and Research Institute (PERI) (2005 – 2007)
PUBLICATIONS

Peer-reviewed Publications:
1. Fleckenstein JL, Weatherall PT, Bertocci LA, Ezaki M, Haller RG, Greenlee RG Jr, Bryan WW, Peshock RM. Locomotor system assessment by muscle magnetic resonance imaging. Magn Reson Quar 1991; 7:79-103.
2. Fleckenstein JL, Watumull D, Conner KE, Ezaki M, Greenlee RG Jr, Bryan WW, Chason DP, Parkey RW, Peshock RM, Purdy PD. Denervated human skeletal muscle: MR imaging evaluation. Radiology 1993; 187:213-218.
3. Pitt AM, Fleckenstein JL, Greenlee RG Jr, Burns DK, Bryan WW, Haller R. MRI-guided biopsy in inflammatory myopathy: initial results. Magn Reson Imaging 1993; 11:1093-1099.
4. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F, Lee MY, Brinkmann JR, Almada A, Gappmaier E, Graves J, Herbelin L, Mendoza M, Mylar D, Smith P, Yu P. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43:1316-1322.
5. Brott T, Tomsick T, Feinberg W, Johnson C, Biller J, Broderick J, Kelly M, Frey J, Schwartz S, Blum C, Nelson JJ, Chambless L, Toole J for the Asymptomatic Carotid Atherosclerosis Study Investigators. Baseline silent cerebral infarction in the asymptomatic carotid atherosclerosis study. Stroke 1994;25:1122-1129.
6. Eliasziw M, Smith RF, Singh N, Holdsworth DW, Fox AJ, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Further comments on the measurement of carotid stenosis from angiograms. Stroke 1994;25:2445-2449.
7. Eliasziw M, Rankin RN, Fox AJ, Haynes RB, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Accuracy and prognostic consequences of ultrasonography in identifying severe carotid artery stenosis. Stroke 1995;26:1747-1752.
8. Eliasziw M, Streifler JY, Spence JD, Fox AJ, Hachinski VC, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Prognosis for patients following a transient ischemic attack with and without a cerebral infarction on brain CT. Neurology 1995;45:428-431.
9. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-1428
10. Gasecki AP, Eliasziw M, Ferguson GG, Hachinski V, Barnett JM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. J Neurosurg 1995;83:778-782.
11. Amato AA, Gronseth GS, Callerame KJ, Kagan-Hallet KS, Bryan WW, Barohn RJ. Tomaculous neuropathy: a clinical and electrophysiologic study in patients with and without deletions in chromosome 17p11.2 Muscle Nerve 1996;19:16-22.
12. Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, Barohn RJ. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996;40:581-586.
13. Howard G, Baker WH, Chambless LE, Howard VJ, Jones AM, Toole JF, for the Asymptomatic Carotid Atherosclerosis Study Investigators. An approach for the use of doppler ultrasound as a screening tool for hemodynamically significant stenosis (despite heterogeneity of doppler performance): A multicenter experience. Stroke 1996;27:1951-1957.
14. Katz JS, Wolfe GI, Burns DK, Bryan WW, Fleckenstein JL, Barohn RJ. Isolated neck extensor myopathy: a common cause of dropped head syndrome. Neurology 1996;46:917-921.
15. Lindsey JT, Bryan WW, Robinson JB Jr, Orenstein HH. The effect of a muscle wrap on nerve healing in a rat model. J Reconstr Microsurg 1996;12:475-478
16. McGuire D, Garrison L, Armon C, Barohn R, Bryan W, Miller R, Parry G, Petajan J, Ross M, SSNJV/CNTF ALS Study Group. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. Neurology 1996;46:1442-1444.
17. Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, Goodpasture JC. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996; 47:1329-1331.
18. Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA, Sloop RR, The WALS Study Group. Placebo-controlled trial of Gabapentin in patients with amyotrophic lateral sclerosis (ALS). Neurology 1996;47:1383-1388.
19. Miller RG, Petajan J, Bryan WW, Armon C, Barohn RJ, Goodpasture J, Hoagland RJ, Parry GJ, Ross MA, Stromatt SC, The rhCNTF ALS Study Group. A placebo-controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-260.
20. The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: Use of normal isometric strength data. Arch Phys Med Rehabil 1996;77:1251-1255.
21. Young B, Moore WS, Robertson JT, Toole FJ, Ernst CV, Cohen SN, Broderick JP, Dempsey RJ, Hosking JD, for the ACAS Investigators. An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. Stroke 1996;27:2216-2224.
22. Castaldo JE, Nelson JJ, Reed JF III, Longenecker JE, Toole JF, for the Asymptomatic Carotid Atherosclerosis Study Investigators. The delay in reporting symptoms of carotid artery stenosis in an at-risk population. Arch Neurol 1997;54:1267-1271.
23. Haley RW, Hom J, Roland PS, Bryan WW, Van Ness PC, Bonte FJ, Devous MD Sr, Mathews D, Fleckenstein JL, Wians FH, Wolfe GI, Kurt TL. Evaluation of neurologic function in Gulf War veterans - a blinded case-control study. JAMA 1997;277:223-230.
24. Hoagland RJ, Mendoza M, Armon C, Miller RG, Bryan WW, Malta E, Parry GJ, Petajan JH, Ross MA, Barohn RJ, Goodpasture JC, The Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group. Reliability of Tufts Quantitative Neuromuscular Examination in a multi-center study in patients with ALS. Muscle & Nerve 1997;20:691-695.
25. Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology 1997;48:700-707.
26. McGuire D, Garrison L, Armon C, Barohn RJ, Bryan WW, Miller R, Parry GJ, Petajan JH, Ross MA. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group. J Neurol Sci 1997;152(Suppl 1):S18-S22.
27. Sansone V, Griggs RC, Meola G, Ptacek LJ, Barohn R, Iannaccone S, Bryan W, Baker N, Janas SJ, Scott W, Ririe D, Tawil R. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol 1997;42:305-312.
28. Wolfe GI, El-Feky WH, Katz JS, Bryan WW, Wians FA Jr, Barohn RJ. Antibody panels in idiopathic polyneuropathy and motor neuron disease. Muscle & Nerve 1997;20:1275-1283.
29. Barnett HJM, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, for the North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-1425.
30. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations SP, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
31. Bryan WW, Reisch JS, McDonald G, Herbelin LL, Barohn RJ, Fleckenstein JL. Magnetic resonance imaging of muscle in amyotrophic lateral sclerosis. Neurology 1998;51:110-113.
32. Jackson CE, Amato AA, Bryan WW, Wolfe GI, Barohn RJ. Primary hyperparathyroidism and amyotrophic lateral sclerosis: Is there a relationship? Neurology 1998;50:1795-1799.
33. Katz JS, Wolfe GI, Bryan WW, Tintner R, Barohn RJ. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1998;50:470-475.
34. Ross MA, Miller RG, Borchert L, Parry G, Barohn RJ, Armon C, Bryan WW, Petajan J, Stromatt S, Goodpasture J, and the rhCNTF ALS Study Group. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. Neurology 1998;50:768-772.
35. The BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999;52:1427-1433
36. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A, BDNF ALS Study Group. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999;169:13-21.
37. Kappelle LJ, Eliasziw M, Fox AJ, Sharpe BL, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. Stroke 1999;30:282-286.
38. Katz JS, Wolfe GI, Andersson PB, Saperstein DS, Elliott J, Nations SP, Bryan WW, Barohn RJ. Brachial amyotrophic diplegia: A slowly progressive motor neuron disorder. Neurology 1999;53:1071-1076.
39. Katz JS, Wolfe GI, Iannaccone S, Bryan WW, Barohn RJ. The exercise test in Andersen's syndrome. Arch Neurol 1999;56:352-356.
40. Nations SP, Wolfe GI, Amato AA, Jackson CE, Bryan WW, Barohn RJ. Distal myasthenia gravis. Neurology 1999;52:632-634.
41. Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, Bryan WW, Burns DK, Barohn RJ. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner Syndrome. Muscle Nerve 1999;22:560-566.
42. Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS, Cha CH, Katz JS, Bryan WW, Barohn RJ. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol 1999;56:540-547.
43. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
44. van der Sluis RW, Wolfe GI, Nations SP, Bryan WW, Krampitz DE, Kissel JT, Barohn RJ. Post-Radiation Lower Motor Neuron Syndrome. J Clin Neuromusc Dis 2000; 2:10-17.
45. Miller RG, Moore DH, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R, and the WALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
46. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagarajara HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ, and The Working Group on Peripheral Neuropathy. Randomized Controlled Trial of IVIg in Untreated Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology 2001;56:445-449.
47. Benavente O, Eliaszaw M, Streifler JY, Fox AJ, Barnett HJM, Meldrum H for the North American Symptomatic Carotid Endarterectomy Trial Collaborators. Prognosis after transient monocular blindness associated with carotid-artery stenosis. N Engl J Med 2001;345:1084-90
48. Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wench M, Myers D, Herbelin L, King R, Smith J, Gelinas D, Miller RG. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001;191:75-78.
49. Miller RG, Moore DH, Dronsky V, Bradley W, Barohn R, Bryan W, Prior TW, Gelinas DF, Iannacone S, Kissel J, Leshner R, Mendell J, Mendoza M, Russman B, Samaha F, Smith S, SMA Study Group. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001; 191:127-131.
50. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ, and Mendell JR, for the Myasthenia Gravis-IVIG Study Group. Randomized, Controlled Trial of Intravenous Immunoglobulin in Myasthenia Gravis. Muscle Nerve 2002; 26: 549-552.
51. Trivedi JR, Wolfe GI, Nations SP, Burns DK, Bryan WW, Dewey RB. Adult Polyglucosan Body Disease Associated With Lewy Bodies and Tremor. Arch Neurol 2003; 60:764-766.
52. Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, Miller RG, Parry GJ, Petajan JH, Ross MA, Stromatt SC, and the rhCNTF ALS Study Group. Can We Eliminate Placebo in ALS Clinical Trials? Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders 2003; 4:11-15.
53. Saperstein DS, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RJ. Challenges in the Identification of Cobalamin-Deficiency Polyneuropathy. Arch Neurol 2003; 60: 1296-1301.
54. Haley RW, Vongpatanasin W, Wolfe GI, Bryan WW, Armitage R, Hoffmann RF, Petty F, Callahan TS, Charuvastra E, Shell WE, Marshall WW, Victor RG. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. Am J of Med. 2004;117:469-478.
55. Salajegheh M, Bryan WW, Dalakas MC. The challenge of diagnosing ALS in patients with prior poliomyelitis. Neurology 2006; 67: 1078-1079.

Publications, not refereed:
1. Jackson C, Bryan WW. Amyotrophic lateral sclerosis. Sem Neurol 1998;18:27-39.
2. Bryan WW. MUNE as an endpoint in clinical trials. In: Bromberg MB (ed.). Motor Unit Number Estimation. Clinical Neurophysiology 2003, 55 (suppl): 324-328.
3. Bryan WW. Regulatory issues in ALS clinical trials. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders 2004; 5 (suppl 1): 36-41
Abstracts:
1. Bryan W, Lewis SF, Bertocci L, Gunder M, Ayyad K, Gustafson P, Haller RG. Muscle lactate dehydrogenase deficiency: a disorder of anaerobic glycogenolysis associated with exertional myoglobinuria. Neurology 1990;41(suppl 1):203.
2. Ringel RP, Murphy JR, Brinkman JR, Lee MY, and the Western ALS Study Group. Natural history of ALS. Neurology 1991;41(suppl 1):313.
3. Miller RG, Bryan WW, Dietz M, Munsat TL, Petajan JH, Smith SA. Safety, tolerability, and pharmacokinetics of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Ann Neurol 1993;34(2):P241.
4. Janas J, Iannaccone S, Bryan W, Barohn RJ, Ptacek L. Andersen's syndrome: report of two cases. J Child Neurol 1994; 9:202.
5. Katz J, Ridings L, Bryan W, Barohn RJ, Jackson CE. The natural history of multifocal motor neuropathy. J Child Neurol 1994; 9:207.
6. Amato AA, Gronseth GS, Bryan WW, Barohn RJ. Tomaculous neuropathy: a clinical and electrophysiologic study in patients with and without deletions in chromosome 17p11.2. J Child Neurol 1995;10:160.
7. Amato AA, Gronseth GS, Callerame KJ, Kagan-Hallet KS, Bryan WW, Barohn RJ. Tomaculous neuropathy: a clinical and electrophysiological study in patients with and without deletions in chromosome 17p11.2. Neurology 1995;45(suppl):A168-169.
8. Bryan WW, Barohn RJ, Murphy JR, Armon C, Miller RG, Goodpasture JE, Parry GJ, Petajan J, Ross MA, Stromatt S, the ALS/SSNJV Study Group. Placebo versus natural history in an ALS clinical trial. Neurology 1995;45(suppl):A280-281
9. Greenfield F, Bryan WW, Katz JS, Barohn RJ. Chronic sensory ataxia: an unusual case. J Child Neurol 1995;10:161.
10. Jetha N, Wolfe GI, Bryan WW, Barohn RJ. Hereditary neuropathy with liability to pressure palsies presenting as chronic progressive sensory-motor polyneuropathy. J Child Neurol 1995;10:162.
11. Katz JS, Wolfe GI, Bryan WW, Burns DK, Barohn RJ. Isolated benign neck extensor myopathies. J Child Neurol 1995;10:162.
12. McGuire D, Garrison L, Armon C, Barohn R, Bryan W, Miller R, Parry G, Petajan J, CNTF ALS Study Group. Tuft's quantitative neuromuscular examination: high correlation with the sickness impact profile in measuring progression of amyotrophic lateral sclerosis. Ann Neurol 1995;38:336 337.
13. Miller RG, Armon C, Barohn R, Bryan W, Goodpasture J, Parry G, Petajan J, Ross M, Stromatt S, the ALS/SSNJV Study Group. A controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis (ALS). Neurology 1995;45(suppl):A281.
14. 14. Ross MA, Parry GJ, Miller RG, Armon C, Barohn R, Bryan WW, Petajan J, Stromatt S, the ALS/SSNJV Study Group. Evaluation of amyotrophic lateral sclerosis diagnostic criteria (ALSDC) for a controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF). Neurology 1995;45(suppl):A280.
15. Wolfe GI, Katz JS, Bryan WW, Barohn RJ. Clinical features of primary lateral sclerosis. J Child Neurol 1995;10:167.
16. Wolfe GI, Katz JS, Bryan WW, Wians FH, Barohn RJ. Antibody panels in idiopathic polyneuropathy and motor neuron disease. Muscle Nerve 1995;18:1069
17. Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, Barohn RJ. Inclusion-body myositis: pattern of weakness and clinical features and evidence supporting the diagnosis of probable inclusion-body myositis. Neurology 1996;46:A234.
18. Baker N, Burns D, Farmer S, Wolfe GI, Bryan WW, Katz J, Barohn RJ. Becker muscular dystrophy presenting in the 7th decade. J Child Neurol 1996;11:150.
19. Baker N, Bryan WW, Haller R, Burns D, Barohn RJ. Myophosphorylase deficiency presenting late in life as a fixed myopathy. J Child Neurol 1996;11:148.
20. Barohn RJ, Bryan WW, Wolfe GI, Jackson CE, Amato AA. Is there a relationship between hyperparathyroidism and amyotrophic lateral sclerosis? J Child Neurol 1996;11:152.
21. Haller RG, Bryan WW, Barohn RJ, Wolfe GI, Burns D, McKnight RM, Farmer S. Recurrent exertional myoglobinuria due to dystrophin deficiency. J Child Neurol 1996;11:152-153.
22. Krampitz D, Bryan WW, Burns D, Haller R, Barohn RJ. Castleman's disease with chronic inflammatory demyelinating polyneuropathy. J Child Neurol 1996;11:149.
23. Krampitz D, Iannaccone ST, Wolfe GI, Burns D, Bryan WW, Barohn RJ. Bethlem myopathy in three generations. J Child Neurol 1996;11:147.
24. Miller RG, Gelinas D, Moore D, Mendoza M, Quien A, Young L, Armon C, Barohn R, Bryan W, Bromberg M, Petajan J, Neville H, Ringel S, Parry G, Ravits J, Ross M, Leiderman D. A placebo-controlled trial of Gabapentin in amyotrophic lateral sclerosis. Neurology 1996;46:A469.
25. Nations SP, Wolfe GI, Burns DK, Bryan WW, Barohn RJ. Clinical features of proximal myotonic myopathy. J Child Neurol 1996;11:147-148
26. Salmon TH, Burns D, Bryan WW, Haller R, Barohn RJ. Atypical adult-onset acid maltase deficiency. J Child Neurol 1996;11:148.
27. Salmon TH, Katz JS, Wolfe GI, Bryan WW, Barohn RJ. Concomitant occurrence of myasthenia gravis and the Lambert-Eaton syndrome. J Child Neurol 1996;11:152.
28. Sansone V, Barohn R, Bryan W, Baker N, Iannaccone S, Scott W, Meola G, Ptacek L, Griggs RC, Tawil R. Evidence of clinical overlap between Andersen's syndrome and typical long QT syndrome: analysis of 10 patients. Ann Neurol 1996;40:544.
29. Wolfe GI, Bryan WW, Barohn RJ. Clinical and molecular features of X-linked Charcot-Marie-Tooth disease. J Child Neurol 1996;11:147.
30. Wolfe GI, Katz JS, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Is conduction block a necessary finding in patients with multifocal motor neuropathy? Neurology 1996;46:A234.
31. Atkinson BR, Herrold JM, Wolfe GI, Nations SP, Burns DK, Bryan WW, Barohn RJ. Motor predominant neuropathy related to glue-sniffing. J Child Neurol 1997;12:135.
32. Herrold JM, Wolfe GI, Bryan WW, Lee WM, Burns DK, Nations SP, Barohn RJ. Isolated peripheral nerve vasculitis in association with hepatitis B infection. J Child Neurol 1997;12:135.
33. Jackson CE, Amato AA, Gronseth G, Iturriaga E, De Moor C, Rhine C, Wolfe GI, Nations SP, Bryan W, Barohn RB (sic). A new myasthenia gravis (MG) grading scale: application in a large cohort of patients. Neurology 1997;48:A65
34. Katz, Bryan WW, Barohn RJ. Bulbospinal spinal muscular atrophy without mutation on the X chromosome. J Child Neurol 1997;12:134
35. Katz JS, Bryan WW, Wolfe GI, Barohn RJ. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1997;48:A64.
36. Nations SP, Herrold JM, Bryan WW, Wolfe GI, Barohn RJ. Hereditary motor sensory neuropathy with vocal cord involvement-type IIC. J Child Neurol 1997;12:134.
37. Nations SP, Wolfe GI, Amato AA, Jackson C, Bryan WW, Barohn RJ. Myasthenia gravis developing after removal of thymoma. J Child Neurol 1997;12:133.
38. Nations SP, Wolfe GI, Amato AA, Jackson CE, Bryan WW, Barohn RJ. Clinical features of patients with distal myasthenia gravis. Neurology 1997;48:A64
39. Venkatesh V, Nations SP, Wolfe GI, Lyde CB, Bryan W, Barohn RJ. Lepromatous mononeuritis multiplex with progression during a reversal reaction. J Child Neurol 1997;12:133.
40. Wasay M, Herrold JM, Burns DK, Kagan-Hallet K, Bryan WW, Barohn RJ, Wolfe GI. Chloroquine myopathy and neuropathy with elevated cerebrospinal fluid protein. J Child Neurol 1997;12:134 135.
41. Iannaccone ST, Nations SP, Bryan WW, Wolfe GI, Barohn RJ. CMT with vocal cord paralysis, type 2C. Neuromusc Disord 1997;7:454-455.
42. Baker NS, Wolfe GI, Nations SP, Bryan WW, Barohn RJ. Cryptogenic sensory polyneuropathy: Clinical and electrophysiologic features. Ann Neurol 1997;42:455.
43. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations SP, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
44. van der Sluis RW, Saperstein DS, Barohn RJ, Burns DK, Bryan WW, Wolfe GI. Chronic inflammatory demyelinating polyneuropathy in a patient with inherited demyelinating polyneuropathy. J Child Neurol 1998;13:137.
45. van der Sluis RW, Wolfe GI, Bryan WW, Krampitz DE, Nations SP, Elliott JL, Barohn RJ. Atypical motor neuron disease as a late complication of radiation therapy. J Child Neurol 1998;13:141-142.
46. Nations SP, Lyde CB, Wolfe GI, Bryan WW, Barohn RJ. Electrophysiologic Studies in leprous neuropathy. J Child Neurol 1998;13:140.
47. Saperstein DS, Herbelin L, Bryan WW, Wolfe GI, Nations SP, Barohn RJ. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. J Child Neurol 1998;13:134.
48. Saperstein DS, Wolfe GI, Haller RG, Bryan WW, Barohn RJ. Hepatis C virus infection and polymyositis. J Child Neurol 1998;13:141.
49. Cha CH, Wolfe GI, Bryan WW, Burns DK, Barohn RJ. Miyoshi myopathy in Hispanic siblings. J Child Neurol 1998;13:134.
50. Barohn RJ, Herbelin L, Wolfe GI, Nations SP, Reisch JS, Bryan WW. The correlation between the myasthenia gravis activity of daily living profile and the quantitative myasthenia gravis score. Neurology 1998;50:A22.
51. Nations SP, Saperstein DS, Wolfe GI, Bryan WW, Barohn RJ. Clinical profile of vitamin B12 neuropathy. Neurology 1998;50:A208-A209.
52. Saperstein DS, Amato AA, Katz JS, Wolfe GI, Nations SP, Bryan WW, Jackson CE, Barohn RJ. Multifocal motor and sensory neuropathy differs from multifocal motor neuropathy. Muscle Nerve 1998;21:1589.
53. Miller RG, Anderson F on behalf of the ALS C.A.R.E. Study Group. The ALS patient care database: A resource for measuring and improving ALS outcomes. Neurology 1998; 50:A245.
54. Alkhersam H, Wolfe GI, Bryan WW, Nations SP, Barohn RJ. Diabetic radiculoplexopathy involving the cervical more than the lumbosacral region. J Child Neurol 1999;14:183.
55. Bauerle JA, Wolfe GI, Nations SP, Rosenberg SA, Bryan WW, Barohn RJ. Vasculitic neuropathy associated with IgA nephropathy and rapidly progressive glomerulonephritis. J Child Neurol 1999; 14:185.
56. Bauerle JA, Wolfe GI, Nations SP, Rosenberg SA, Bryan WW, Barohn RJ. Vasculitic neuropathy associated with IgA nephropathy and rapidly progressive glomerulonephritis. J Child Neurol 1999; 14:185.
57. Miller RG, Gelinas D, Moore D, Mendoza M, Watamura S, Barohn R, Bryan W, Bromberg M, Petajan J, Neville H, Ringel S, Parry G, Ravits J, Ross M, Bosch P, Smith B, Graves M, Jackson C, Amato A, Johnston W, Mandler R, Olney R. A phase III placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis. Ann Neurol 1999;46:494.
58. Miller RG, Moore DH, Bryan WW, Barohn RJ, Petajan JH, Neville HE, Ringel Sp, Murphy JR, Parry GJ, Ravits J, Ross M and the WALS Study. Prognostic factors in ALS: Predicting rate of decline in strength and FVC. Neurology 1999; 52:A164-A165
59. Nations SP, Lyde CB, Herbelin LL, Wolfe GI, Bryan WW, Barohn RJ. Hansen's disease in the U.S.: experience in a regional HD clinic. Neurology 1999; 52:A420.
60. Pettigrew LC, Thomas N, Hosking J, Howard VJ, Veltkamp RE, Toole JF, ACAS Investigators. Mini-mental status as a predictor of outcome in asymptomatic carotid arterial stenosis. Neurology 1999; 52:A149.
61. Ross MA, Bryan WW, Hoagland R, Brooks BR, Parry GJ, Miller RG, and the ALS C.A.R.E. Study Group. Application of the El Escorial ALS diagnostic criteria in clinical practice. Neurology 1999; 52:A163.
62. Saperstein DS, Collins MP, Wolfe GI, Nations SP, Haller RG, Burns DK, Bryan WW, Barohn RJ. Hepatitis C infection and inflammatory myopathy. Neurology 1999; 52:A451-A452.
63. Saperstein DS, Katz JS, Wolfe GI, Nations SP, Burns DK, Bryan WW, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. J Child Neurol 1999;14:183.
64. Cheema Z, Bryan WW, Elliott JL, Nations SP, Wolfe GI, Barohn RJ, Prior TW. Clinical and electrophysiologic features of adult-onset spinal muscular atrophy patients with and without the spinal muscular atrophy gene mutation. J Child Neurol 2000;15:200.
65. Cheema ZF, Wolfe GI, Nations SP, Bryan WW, Burns DK, Barohn RJ, Holland N, Pascuzzi R. Plasmacytomas initially undetected in the setting of paraprotein-associated chronic inflammatory demyelinating polyneuropathy. J Child Neurol 2000;15:201
66. Kojan S, Cheema Z, Nations SP, Wolfe GI, Bryan WW, Barohn RJ. Neurophysiologic abnormalities in adrenomyeloneuropathy: selective central and peripheral nervous system involvement. J Child Neurol 2000;15:197.
67. Kojan S, Goodwin WE, Bryan WW, Nations SP, Burns DK, Barohn RJ, Wolfe GI. Clinical and laboratory features of primary lateral sclerosis. J Child Neurol 2000;15:200.
68. Kojan S, Wolfe GI, Bryan WW, Nations SP, Iannaccone ST, Barohn RJ. A woman with the phenotype of Emery-Dreifuss muscular dystrophy. J Child Neurol 2000;15:194
69. Manek S, Nations SP, Wolfe GI, Bryan WW, Burns DK, Barohn RJ. Multifocal acquired demyelinating sensory and motor neuropathy responds to intravenous immunoglobulin. J Child Neurol 2000;15:193.
70. Manek S, Nations SP, Wolfe GI, Bryan WW, Burns DK, Barohn RJ. Idiopathic chronic sensory ataxia: where is the lesion? J Child Neurol 2000;15:193.
71. Nanjiani Z, Ugokwe C, Iannaccone ST, Nations SP, Wolfe GI, Bryan WW, Burns DK, Barohn RJ. Familial Achilles tendon contractures and myalgias in the central core myopathy-malignant hyperthermia complex. J Child Neurol 2000;15:192.
72. Nanjiani Z, Nations SP, Elliott JL, Wolfe GI, Bryan WW, Barohn RJ. Distal hereditary motor neuropathy: A distinct form of Charcot-Marie-Tooth disease. J Child Neurol 2000;15:200-201.
73. Jackson CE, Rosenfeld J, Bryan WW, Barohn RJ, Gelinas DF, Miller RG. A Prospective Evaluation of Pulmonary Function Studies and Symptoms of Hypoventilation in ALS Patients. Amyotrophic Lateral Sclerosis 2000;1(suppl 3):21.
74. Miller RG, Gelinas DF, Moore D, Dronsky V, Mendoza M, Barohn RJ, Bryan WW, Iannaccone S, Kissel J, Mendell J, Russman B, Bradley WG, Leshner R, Smith S, Samaha F, and the SMA Study Group. A Phase III Placebo-Controlled Trial of Gabapentin in Spinal Muscular Atrophy. Amyotrophic Lateral Sclerosis 2000;1(suppl 3):23.
75. Cheema ZF, Khatri I, Wolfe GI, Nations SP, Bryan WW, Barohn RJ. Acquired Auditory Neuropathy Associated With Acute Sensorimotor Polyneuropathy. J Child Neurol 2001;16:205.
76. Herbelin LL, Nations SP, Wolfe GI, Foster BM, Bryan WW, Barohn RJ. The Correlation between Static Fatigue Testing and the Quantitative Myasthenia Gravis Score and Activities of Daily Living Profile. Neurology 2001; 56 (suppl 3):A63.
77. Miller RG, Gelinas DF, Moore DH, Dronsky V, Mendoza M, Barohn RJ, Bryan WW, Iannaccone ST, Kissel JT, Mendell JR, Prior TW, Russman BS, Bradley WG, Leshner RT, Smith SA, Samaha FJ, Watamura S, Hardin K, Herbelin L, King W, McCullar C, Steele J, Anderson A, Mayhew J, Nowariac C, Schweiterman D, and the SMA Study Group. The Natural History of Spinal Muscular Atrophy. Neurology 2001; 56 (suppl 3):A316.
78. Trivedi JR, Wolfe GI, Nations SP, Burns DK, Bryan WW, Dewey RB. Adult Polyglucosan Body Disease Presenting With Levodopa-Responsive Tremor. J Child Neurol 2002; 17: 2.
79. Cheema ZF, Wolfe GI, Nations SP, Herbelin L, Akram Y, Bryan WW, Barohn RJ. Comparing Clinical, Electrophysiologic, and Laboratory Features of Adult spinal Muscular Atrophy (SMA) Patients with and without Survival Motor Neuron (SMN) Gene Mutation. Neurology 2002; 58 (suppl 3):A465-A466.
80. Saperstein DS, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RB. Identification of Cobalamin Deficiency in a neuropathy clinic. JPNS 2003; 8 (suppl 1):56.

Book Chapter:
Katz JS, Bryan WW, Barohn RJ. Infections and granulomatous neuropathy. In: Samuels MA, Feske S (eds.). Office Practice of Neurology, Churchill Living

Page Updated June 16, 2008

 
Copyright © 2007  Biologics Consulting Group, Inc. - All Rights Reserved